Rallybio Announces RLYB212 And RLYB332 Preclinical Data At The 66th ASH Annual Meeting
Rallybio Announces RLYB212 And RLYB332 Preclinical Data At The 66th ASH Annual Meeting
Rallybio在第66届ASH年会上发布了RLYB212和RLYB332的临床前数据
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the presentation of two posters highlighting promising preclinical data for pipeline candidates RLYB212 and RLYB332 at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7–10, 2024 in San Diego, California.
Rallybio Corporation（纳斯达克股票代码：RLYB）是一家临床阶段的生物技术公司，将科学进步转化为针对毁灭性罕见疾病患者的变革性疗法。该公司今天宣布在2024年12月7日至10日在加利福尼亚州圣地亚哥举行的第66届美国血液学会（ASH）年会和博览会上发布两张海报，重点介绍在研候选药物 RLYB212 和 RLYB332 的临床前数据。
资讯热榜
更新时间